Literature DB >> 17562956

Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study.

Thomas Arentz1, Reinhold Weber, Gerd Bürkle, Claudia Herrera, Thomas Blum, Jochem Stockinger, Jan Minners, Franz Josef Neumann, Dietrich Kalusche.   

Abstract

BACKGROUND: Pulmonary vein (PV) isolation is a promising new treatment for atrial fibrillation (AF). We hypothesized that isolation of large areas around both ipsilateral PVs with verification of conduction block is more effective than the isolation of each individual PV. METHODS AND
RESULTS: A total of 110 patients, 67 with paroxysmal AF and 43 with persistent AF, were randomly assigned to undergo either isolation of each individual PV or isolation of large areas around both ipsilateral PVs. The isolation of each individual PV was an electrophysiologically guided, ostial segmental ablation with a 64-pole basket catheter or a 20-pole circular mapping catheter (group I). Isolation of large areas was performed around the 2 ipsilateral veins with a nonfluoroscopic navigation system and a circular 20-pole mapping catheter for verification of conduction block (group II). In both groups, an irrigated-tip ablation catheter (25 to 35 W) was used to achieve complete isolation. Procedure and ablation times were longer in group II, whereas fluoroscopic time was significantly shorter (P < or = 0.001). After a follow-up period of 15+/-4 months, 27 patients in group I (49%) and 37 patients in group II (67%) remained free of symptoms of AF and had no AF or atrial flutter during repetitive Holter monitoring without antiarrhythmic drug treatment after a single procedure (P < or = 0.05).
CONCLUSIONS: The rate of success was significantly higher and fluoroscopy times were significantly lower in the group with large isolation areas around both ipsilateral PVs than in those who underwent individual PV isolation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562956     DOI: 10.1161/CIRCULATIONAHA.107.690578

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  63 in total

1.  Pulmonary venous isolation versus additional substrate modification as treatment for paroxysmal atrial fibrillation.

Authors:  Andrew Robertson Gavin; Cameron B Singleton; John Bowyer; Andrew D McGavigan
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

2.  Automatic planning of atrial fibrillation ablation lines using landmark-constrained nonrigid registration.

Authors:  Martin Koch; Alexander Brost; Felix Bourier; Joachim Hornegger; Norbert Strobel
Journal:  J Med Imaging (Bellingham)       Date:  2014-05-22

Review 3.  Catheter ablation for atrial fibrillation.

Authors:  Steven A Lubitz; Avi Fischer; Valentin Fuster
Journal:  BMJ       Date:  2008-04-12

4.  Transverse shifting of the esophagus according to the patient's position helped achieve a safe and successful pulmonary vein isolation procedure.

Authors:  Koichiro Ejima; Morio Shoda; Keisuke Futagawa; Ryusuke Kimura; Tetsuyuki Manaka; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

5.  Accuracy of left atrial anatomical maps acquired with a multielectrode catheter during catheter ablation for atrial fibrillation.

Authors:  Jacob S Koruth; E Kevin Heist; Stephan Danik; Conor D Barrett; Rajesh Kabra; Dan Blendea; Jeremy Ruskin; Moussa Mansour
Journal:  J Interv Card Electrophysiol       Date:  2011-04-19       Impact factor: 1.900

6.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

7.  Catheter ablation of persistent atrial fibrillation: The importance of substrate modification.

Authors:  Konstantinos P Letsas; Michael Efremidis; Nikolaos P Sgouros; Konstantinos Vlachos; Dimitrios Asvestas; Antonios Sideris
Journal:  World J Cardiol       Date:  2015-03-26

Review 8.  Efficacy of selective arrhythmogenic pulmonary veins isolation versus empirical all pulmonary veins isolation for atrial fibrillation: a meta-analysis of randomized and observational studies.

Authors:  Baowei Zhang; Ya Zhen; Aibin Tao; Guohui Zhang
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

9.  [Catheter ablation of paroxysmal atrial fibrillation. Optimal approach and result].

Authors:  Shibu Mathew; Andreas Metzner; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-04-16

10.  Acute and long-term results of PVI at antrum using a novel high-density mapping catheter without help of 3D electro-anatomic mapping in patients with paroxysmal and chronic atrial fibrillation.

Authors:  Thomas Neumann; Malte Kuniss; Damir Erkapic; Sergey Zaltsberg; Alexander Berkowitsch; Dimitri Pajitnev; Maciej Wojcik; Sebastien Janin; Christian W Hamm; Heinz F Pitschner
Journal:  J Interv Card Electrophysiol       Date:  2010-01-20       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.